The Use of Vitamins and Minerals in Skeletal Health: American Association of Clinical Endocrinologists and the American College of Endocrinology Position Statement

Hurley, Daniel L.; Binkley, Neil; Camacho, Pauline M.; Diab, Dima L.; Kennel, Kurt A.; Malabanan, Alan O.; Tangpricha, Vin

doi:10.4158/ps-2018-0050

Cited by 7 publications

(7 citation statements)

References 103 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anyway, based on evidence derived from studies in postmenopausal osteoporotic women, the same therapeutic approach is commonly applied in men. A daily calcium intake of 1000 mg for men under 70 years and 1200 mg for men over 70 years is generally suggested, and calcium supplementation should be prescribed only if dietary intake is inadequate (79).…”

Section: Supplement and Replacement Therapymentioning

confidence: 99%

“…Vitamin D supplementation is often necessary, as hypovitaminosis D is common in the elderly mainly as a result of reduced sunlight exposure and a decreased functional capacity of the skin. Furthermore, many conditions (Table 1) associated with osteoporosis are characterized by low levels of vitamin D. Dietetic supplementation of vitamin D is not able to restore normal levels of 25-hydroxy vitamin D, therefore, aside with adequate sun exposure, guidelines suggest supplementation in an individualized dose, based on serum 25-hydroxy vitamin D levels, starting from 800 UI/day (79). Although treatment of hypovitaminosis D is not under the scope of this review, an important point to highlight is that the choice to supplement with the inactivated form of vitamin D (cholecalciferol) or with the 25-hydroxylated form (calcifediol) should consider also the pathogenesis of hypovitaminosis.…”

Section: Supplement and Replacement Therapymentioning

confidence: 99%

See 1 more Smart Citation

MANAGEMENT OF ENDOCRINE DISEASE: Male osteoporosis: diagnosis and management - should the treatment and the target be the same as for female osteoporosis?

Porcelli

Maffezzoni

Pezzaioli

et al. 2020

European Journal of Endocrinology

View full text Add to dashboard Cite

Male osteoporosis has been neglected for too long time and there is need for a change. This condition is clearly under-estimated, under-diagnosed and under-treated. The diagnosis is often made late in the natural history of the pathology or even after a fracture event. Guidelines on screening politics do not agree whether and when men should be considered, and clinical trials are far less performed in men with respect to women. Actually, most of our knowledge on male osteoporosis, especially regarding treatment, is extrapolate from the female counterpart. Male osteoporosis is frequently secondary to other conditions and often associated with comorbidities. Therefore, identification of specific causes of male osteoporosis is essential to drive a correct and personalized treatment. Moreover, men have more osteoporosis-related complications and higher mortality rate associated with fractures. Furthermore, not only fewer men receive a correct and timely diagnosis, but also fewer men receive adequate treatment, and adherence to therapy is far less in men than in women. Of note, very few studies assessed the effect of anti-osteoporotic treatments in men and most of them considered only bone density as primary endpoint. This review focuses on the areas that are still nebulous in male osteoporosis field, from identification of subjects who need to be evaluated for osteoporosis and screening programs dealing with primary prevention, to diagnostic procedures for good estimates of bone quantity and quality and precise calculation of fracture risk, and personalized treatment that take into account the pathophysiology of osteoporosis.

show abstract

Section: Supplement and Replacement Therapymentioning

confidence: 99%

Section: Supplement and Replacement Therapymentioning

confidence: 99%

MANAGEMENT OF ENDOCRINE DISEASE: Male osteoporosis: diagnosis and management - should the treatment and the target be the same as for female osteoporosis?

Porcelli

Maffezzoni

Pezzaioli

et al. 2020

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…The initial search yielded 561 references, 60 CGs were selected for full‐text review and 34 guidelines 46‐79 were included in the final analysis (Figure 1). These included 12 (35.3%) guidelines from Europe, 10 (29.4%) from North America, five (14.7%) from Asia, two (5.9%) from Oceania, two (5.9%) from South America and three (8.8%) from international organisations.…”

Section: Resultsmentioning

confidence: 99%

Vitamin D recommendations in clinical guidelines: A systematic review, quality evaluation and analysis of potential predictors

et al. 2021

View full text Add to dashboard Cite

Background: Vitamin D has been widely promoted for bone health through supplementation and fortification of the general adult population. However, there is growing evidence that does not support these strategies. Our aim is to review the quality and recommendations on vitamin D nutritional and clinical practice guidelines and to explore predictive factors for their direction and strength. Methods:We searched three databases and two guideline repositories from 2010 onwards. We performed a descriptive analysis, a quality appraisal using AGREE II scores (Appraisal of Guidelines Research and Evaluation) and a bivariate analysis evaluating the association between direction and strength of recommendations, AGREE II domains' scores and pre-specified characteristics. Results:We included 34 guidelines, 44.1% recommended, 26.5% suggested and 29.4% did not recommend vitamin D supplementation. Guidelines that scored higher for "editorial independence" and "overall quality score" were less likely to recommend or suggest vitamin D supplementation (median 68.8 vs 35.4; P = .001 and 58.3

show abstract

“…Vitamin D, calcium and weight bearing activity should be encouraged for all transgender persons to ensure optimal bone health. Studies (19,31) examining vitamin D status in transgender adults have demonstrated mean serum 25-hydroxyvitamin D (25(OH)D) concentrations below the optimal level of 30 ng/mL (75 nmol/L) as suggested by the Endocrine Society (32) and American Association of Clinical Endocrinologists (33). Van Caenegem et al reported that the low vitamin D status in transgender women could be due to decreased physical activity (19).…”

Section: Non-pharmacologic Therapy In Transgender Persons For Bone Hementioning

confidence: 99%

“…All transgender persons should be encouraged to ingest at least 1,000 mg of calcium and 800-1,000 IU of vitamin D from the diet and engage in regular weight bearing activity (33). Those with risk factors for vitamin D deficiency such as BMI >27 or inadequate dietary intake of vitamin D should have a serum 25(OH)D measurement.…”

Section: Non-pharmacologic Therapy In Transgender Persons For Bone Hementioning

confidence: 99%

Osteoporosis and Bone Health in Transgender Persons

Stevenson

Tangpricha

2019

Endocrinology and Metabolism Clinics of North America

Self Cite

View full text Add to dashboard Cite

Purpose of review: To summarize the current studies, systematic reviews, and clinical practice guidelines pertaining to the screening, diagnosis, and treatment of osteoporosis in transgender persons. Recent findings: Gender affirming hormone therapy has been shown to maintain or promote acquisition of bone density as measured by dual-energy x-ray absorptiometry in transgender men and women. No differences in fracture rates have been seen in trans women or men in short, prospective trials. Trans children and adolescents on gonadotropin-releasing hormone may be at risk for decreasing bone density while not on sex steroid hormone replacement. Summary: Ongoing research is needed to determine the clinical significance of changes in bone density in relation to fracture risk. Screening for osteoporosis should be based on assessment of clinical factors including hormone therapy compliance, gonadal removal, and additional osteoporosis risk factors. Post-pubertal trans children and adolescents on gonadotropin-releasing hormone without sex steroid hormone therapy may be at risk for decreasing bone density. Treatment for osteoporosis in trans men and women follows the same guidelines as cisgender populations and should take into consideration both pharmacologic and non-pharmacologic interventions.

show abstract

The Use of Vitamins and Minerals in Skeletal Health: American Association of Clinical Endocrinologists and the American College of Endocrinology Position Statement

Cited by 7 publications

References 103 publications

MANAGEMENT OF ENDOCRINE DISEASE: Male osteoporosis: diagnosis and management - should the treatment and the target be the same as for female osteoporosis?

MANAGEMENT OF ENDOCRINE DISEASE: Male osteoporosis: diagnosis and management - should the treatment and the target be the same as for female osteoporosis?

Vitamin D recommendations in clinical guidelines: A systematic review, quality evaluation and analysis of potential predictors

Osteoporosis and Bone Health in Transgender Persons

Contact Info

Product

Resources

About